Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deffered Revenue: 2009-2024

Historic Non-Current Deffered Revenue for Gyre Therapeutics (GYRE) over the last 11 years, with Dec 2024 value amounting to $928,000.

  • Gyre Therapeutics' Non-Current Deffered Revenue rose 368.11% to $866,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $866,000, marking a year-over-year increase of 368.11%. This contributed to the annual value of $928,000 for FY2024, which is 335.68% up from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Non-Current Deffered Revenue is $928,000, which was up 335.68% from $213,000 recorded in FY2023.
  • Gyre Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $928,000 during FY2024, with a 5-year trough of $118,000 in FY2022.
  • For the 3-year period, Gyre Therapeutics' Non-Current Deffered Revenue averaged around $419,667, with its median value being $213,000 (2023).
  • Data for Gyre Therapeutics' Non-Current Deffered Revenue shows a peak YoY spiked of 335.68% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Gyre Therapeutics' Non-Current Deffered Revenue stood at $118,000 in 2022, then surged by 80.51% to $213,000 in 2023, then spiked by 335.68% to $928,000 in 2024.